Lieff Cabraser partner Brendan Glackin will speak at the ABA Litigation Section Antitrust Litigation Committee’s Hybrid Regional CLE program, “Antitrust Trials: Recent Experiences with Parallel Litigation,” on Wednesday, February 12, 2025, at the University of California College of Law–San Francisco.
The program, designed for litigators and in-house counsel involved in antitrust civil and criminal conduct trials, parallel litigation, and state enforcement authority, will feature insights from plaintiffs’ and defense counsel, attorneys from the DOJ, FTC, California AG’s Office, and esteemed judges.
Brendan will participate in the “Parallel Litigation” panel alongside:
- Moderator: Richard Powers, Kressin Meador Powers, New York, NY
- Paula Blizzard, Attorney General’s Office at California Department of Justice Antitrust Section, San Francisco, CA
- Chris Carlberg, U.S. Department of Justice Antitrust Division, San Francisco, CA
- The Hon. Yvonne Gonzalez Rogers, U.S. District Court for the Northern District of California, Oakland, CA
For the full agenda and list of speakers, visit the ABA’s website.
About Brendan P. Glackin
The Chair of Lieff Cabraser’s Antitrust practice group, Brendan P. Glackin has represented direct purchasers of titanium dioxide in a nationwide antitrust class action lawsuit ($163.5 million in settlements); direct purchasers of flat-panel TV screens in litigation against the world’s leading LCDs manufacturers for conspiring to fix prices ($470 million in settlements; retailers in a monopolization pricing lawsuit against Abbott Laboratories charging that the company exploited the market for AIDS medicines used in conjunction with Abbott’s prescription drug Norvir, and employees in the high-tech workers class action alleging that major Silicon Valley firms colluded to reduce competition for workers.
Brendan has contributed groundbreaking work in litigation against drug makers for blocking access to affordable generics. This includes the blockbuster brand-name prescription drug Cipro ($399 million in settlements), which led to a 2016 “California Lawyer Attorney of the Year” (CLAY) award. Brendan continued his work in the field of generic drugs as lead counsel for Nashville General Hospital (the Hospital Authority of Metropolitan Government of Nashville) in a class-action antitrust case against defendants for monopolizing enoxaparin, the generic version of the blockbuster life-saving anti-coagulant Lovenox, which in 2019, settled for $120 million, the second largest indirect-purchaser antitrust pharmaceutical settlement fund in history, after Cipro.
Contact us
Use the form below to contact a lawyer at Lieff Cabraser.